BBNX · Company research
Beta Bionics, Inc. (BBNX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
54records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose serious safety deficiencies and customer complaints, understating regulatory risks and safety concerns during the period from July 30, 2025 to February 24, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 18, 2026 | bearish | -1 | 1 |
| ROSEN, A LONGSTANDING FIRM, Encourages AppLovin Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – APP | Rosen Law Firm has filed securities class action lawsuits against AppLovin Corporation, Lincoln Educational Services Corporation, and Beta Bionics, Inc. The AppLovin lawsuit alleges the company made false statements regarding AI video creative features and overstated the benefits of its AI models. Investors who purchased securities during specified class periods are encouraged to seek counsel before upcoming lead plaintiff deadlines. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bearish | -1 | 1 |
| ROSEN, A LONGSTANDING FIRM, Encourages AppLovin Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – APP | Rosen Law Firm has filed securities class action lawsuits against AppLovin Corporation, Lincoln Educational Services Corporation, and Beta Bionics, Inc. The AppLovin lawsuit alleges the company made false statements regarding AI video creative features and overstated the benefits of its AI models. Investors who purchased securities during specified class periods are encouraged to seek counsel before upcoming lead plaintiff deadlines. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bearish | -1 | 1 |
| BBNX DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BBNX | Rosen Law Firm is notifying Beta Bionics, Inc. investors of a November 3, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false statements about its iLet Bionic Pancreas insulin pump, which the FDA found to be malfunctioning and causing dangerously high insulin dosing. The company allegedly failed to implement meaningful corrective actions despite thousands of complaints and hundreds of life-threatening events. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bearish | -1 | 1 |
| BBNX DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BBNX | Rosen Law Firm is notifying Beta Bionics, Inc. investors of a November 3, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false statements about its iLet Bionic Pancreas insulin pump, which the FDA found to be malfunctioning and causing dangerously high insulin dosing. The company allegedly failed to implement meaningful corrective actions despite thousands of complaints and hundreds of life-threatening events. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bearish | -1 | 1 |
| SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX - Morningstar | SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX Morningstar | View source ↗ | Morningstar | Oct 15, 2026 | neutral | 0 | 0.6 |
| Beta Bionics, Inc. Class Action Reminder - Robbins LLP Encourages BBNX Investors to Contact the Firm for Information About Their Rights | Robbins LLP reminds investors of a class action lawsuit against Beta Bionics (BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company failed to disclose serious FDA concerns about device malfunctions causing dangerously high insulin doses and hypoglycemic events. Stock fell from $31.99 to $12.89 per share between January and February 2026 following FDA warning letter disclosures. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| Beta Bionics, Inc. Class Action Reminder - Robbins LLP Encourages BBNX Investors to Contact the Firm for Information About Their Rights | Robbins LLP reminds investors of a class action lawsuit against Beta Bionics (BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company failed to disclose serious FDA concerns about device malfunctions causing dangerously high insulin doses and hypoglycemic events. Stock fell from $31.99 to $12.89 per share between January and February 2026 following FDA warning letter disclosures. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Beta Bionics, Inc. for alleged securities fraud. The complaint alleges that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump, including undisclosed quality management deficiencies and unreported serious customer injuries. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Beta Bionics, Inc. for alleged securities fraud. The complaint alleges that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump, including undisclosed quality management deficiencies and unreported serious customer injuries. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline | A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels causing hypoglycemic events, and that the company failed to disclose thousands of complaints to the FDA. Investors who purchased stock between July 30, 2025 and February 24, 2026 can apply to be lead plaintiff by November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline | A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels causing hypoglycemic events, and that the company failed to disclose thousands of complaints to the FDA. Investors who purchased stock between July 30, 2025 and February 24, 2026 can apply to be lead plaintiff by November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| AEVEX Corp. Notice of October 20, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline | Kahn Swick & Foti, LLC announces class action securities lawsuits against AEVEX Corp., Beta Bionics, Inc., and York Space Systems, Inc. The primary case alleges that AEVEX and its executives concealed a pre-arranged plan to prematurely override a 180-day lock-up commitment, allowing Madison to sell shares and generate over $200 million through a secondary offering. Investors who purchased shares during the class periods have until the specified deadlines to request lead plaintiff status. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| AEVEX Corp. Notice of October 20, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline | Kahn Swick & Foti, LLC announces class action securities lawsuits against AEVEX Corp., Beta Bionics, Inc., and York Space Systems, Inc. The primary case alleges that AEVEX and its executives concealed a pre-arranged plan to prematurely override a 180-day lock-up commitment, allowing Madison to sell shares and generate over $200 million through a secondary offering. Investors who purchased shares during the class periods have until the specified deadlines to request lead plaintiff status. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bearish | -1 | 1 |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX | Pomerantz Law Firm has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) alleging securities fraud related to its iLet insulin pump device. The company allegedly misrepresented FDA concerns and failed to properly report thousands of patient complaints. The lawsuit follows significant stock price declines after the FDA issued a warning letter in February 2026, revealing more serious safety and reporting issues than Beta Bionics had previously disclosed. Investors have until November 3, 2026, to join the class action. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bearish | -1 | 1 |
| INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX | Pomerantz Law Firm has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) alleging securities fraud related to its iLet insulin pump device. The company allegedly misrepresented FDA concerns and failed to properly report thousands of patient complaints. The lawsuit follows significant stock price declines after the FDA issued a warning letter in February 2026, revealing more serious safety and reporting issues than Beta Bionics had previously disclosed. Investors have until November 3, 2026, to join the class action. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bearish | -1 | 1 |
| Markets & Stocks - FinancialContent | Markets & Stocks FinancialContent | View source ↗ | FinancialContent | Oct 13, 2026 | neutral | 0 | 0.6 |
| BETA BIONICS, INC. (BBNX) SHAREHOLDER ALERT Bernstein - GlobeNewswire | BETA BIONICS, INC. (BBNX) SHAREHOLDER ALERT Bernstein GlobeNewswire | View source ↗ | GlobeNewswire | Oct 13, 2026 | neutral | 0 | 0.6 |
| BBNX Stock Alert: Beta Bionics Medical Device Safety Issues and Subsequent 37% Stock Drop Trigger Securities Fraud Class Action for Investors - TradingView | BBNX Stock Alert: Beta Bionics Medical Device Safety Issues and Subsequent 37% Stock Drop Trigger Securities Fraud Class Action for Investors TradingView | View source ↗ | TradingView | Oct 13, 2026 | neutral | 0 | 0.6 |
| Beta Bionics (BBNX) Faces Class Action After 37% Stock Drop - TradingView | Beta Bionics (BBNX) Faces Class Action After 37% Stock Drop TradingView | View source ↗ | TradingView | Oct 13, 2026 | neutral | 0 | 0.6 |
| ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX | A securities class action lawsuit has been filed against Beta Bionics, Inc. (BBNX) for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and delivering dangerously high insulin doses, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation. The lead plaintiff deadline is November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 12, 2026 | bearish | -1 | 1 |
| Markets & Stocks - FinancialContent | Markets & Stocks FinancialContent | View source ↗ | FinancialContent | Oct 12, 2026 | neutral | 0 | 0.6 |
| Beta Bionics, Inc. (BBNX) stock price, news, quote and history - Yahoo Finance Australia | Beta Bionics, Inc. (BBNX) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 10, 2026 | neutral | 0 | 0.6 |
| ROSEN, A LEADING LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX | Rosen Law Firm is urging investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, which the FDA found was malfunctioning and dosing patients with dangerously high insulin levels. The firm claims thousands of complaints were filed with the FDA, contradicting defendants' assertions that issues were benign. The lead plaintiff deadline is November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 10, 2026 | bearish | -1 | 1 |
| BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - HBSS | Beta Bionics (NASDAQ: BBNX) faces a securities class action lawsuit for allegedly misleading investors about its iLet automated insulin delivery system. The company concealed thousands of safety complaints, including life-threatening hypoglycemic events, and failed to report them to the FDA as required. An FDA warning letter in February 2026 revealed the violations, causing significant shareholder losses during the class period of July 30, 2025 to February 24, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bearish | -1 | 1 |
| BBNX Investor Alert: Beta Bionics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky - FinancialContent | BBNX Investor Alert: Beta Bionics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky FinancialContent | View source ↗ | FinancialContent | Oct 9, 2026 | neutral | 0 | 0.6 |
| Beta Bionics (BBNX) Stock Fair Value Rises After Mint Clearance And Analyst Target Changes - Yahoo Finance | Beta Bionics (BBNX) Stock Fair Value Rises After Mint Clearance And Analyst Target Changes Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| BBNX Deadline Alert: SueWallSt Reminds Beta Bionics, Inc. (BBNX) Investors of Securities Class Action Deadline on November 3, 2026 - PR Newswire | BBNX Deadline Alert: SueWallSt Reminds Beta Bionics, Inc. (BBNX) Investors of Securities Class Action Deadline on November 3, 2026 PR Newswire | View source ↗ | PR Newswire | Oct 8, 2026 | neutral | 0 | 0.6 |
| BBNX UPCOMING DEADLINE: Levi & Korsinsky Alerts Beta Bionics, Inc. Stockholders of Securities Class Action - Contact the Firm - PR Newswire | BBNX UPCOMING DEADLINE: Levi & Korsinsky Alerts Beta Bionics, Inc. Stockholders of Securities Class Action - Contact the Firm PR Newswire | View source ↗ | PR Newswire | Oct 7, 2026 | neutral | 0 | 0.6 |
| Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline | A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels causing hypoglycemic events, and that the company failed to disclose thousands of complaints to the FDA. Investors who purchased stock between July 30, 2025 and February 24, 2026 can apply to be lead plaintiff by November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bearish | -1 | 1 |
| Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline | A class action securities lawsuit has been filed against Beta Bionics, Inc. for allegedly making false statements about its iLet Bionic Pancreas insulin pump. The lawsuit claims the device's automated dosing algorithm malfunctioned, delivering dangerously high insulin levels causing hypoglycemic events, and that the company failed to disclose thousands of complaints to the FDA. Investors who purchased stock between July 30, 2025 and February 24, 2026 can apply to be lead plaintiff by November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bearish | -1 | 1 |
| SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire | SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A GlobeNewswire | View source ↗ | GlobeNewswire | Oct 6, 2026 | neutral | 0 | 0.6 |
| Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics, Inc. (UNCY), Hims & Hers Health, Inc. (HIMS), and Beta Bionics, Inc. (BBNX) Announced by Holzer & Holzer, LLC | Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics, Inc. (UNCY), Hims & Hers Health, Inc. (HIMS), and Beta Bionics, Inc. (BBNX) Announced by Holzer & Holzer, LLC | Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| BBNX Stock Notice: Beta Bionics Stock Plummeted 37% after Medical Device Safety Issues Disclosed - Securities Fraud Class Action Filed - TradingView | BBNX Stock Notice: Beta Bionics Stock Plummeted 37% after Medical Device Safety Issues Disclosed - Securities Fraud Class Action Filed TradingView | View source ↗ | TradingView | Oct 6, 2026 | neutral | 0 | 0.6 |
| BBNX Stock Notice: Beta Bionics Stock Plummeted 37% after Medical Device Safety Issues Disclosed - Securities Fraud Class Action Filed - Lelezard | BBNX Stock Notice: Beta Bionics Stock Plummeted 37% after Medical Device Safety Issues Disclosed - Securities Fraud Class Action Filed Lelezard | View source ↗ | Lelezard | Oct 6, 2026 | neutral | 0 | 0.6 |
| Deadline Alert: Beta Bionics, Inc. (BBNX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit | A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging securities fraud for failing to disclose material information about FDA safety violations and product issues. The company allegedly omitted over 18,000 complaints including life-threatening hypoglycemic events from FDA reports and misrepresented the severity of FDA observations. The lawsuit covers investors who purchased shares between July 30, 2025 and February 24, 2026, with a November 3, 2026 deadline to file as lead plaintiff. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bearish | -1 | 1 |
| ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX | A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious safety concerns including device malfunctions and dangerously high insulin dosing causing hypoglycemic events. The lawsuit claims Beta Bionics failed to implement meaningful corrective actions despite thousands of complaints. Investors who purchased stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff. | View source ↗ | GlobeNewswire Inc. | Oct 3, 2026 | bearish | -1 | 1 |
| Kaplan Fox Alerts GoDaddy Inc. (NYSE: GDDY) Investors to an Approaching Lead Plaintiff Deadline on October 20, 2026 | A class action lawsuit has been filed against GoDaddy Inc. for allegedly making false and misleading statements about customer growth strategy while implementing promotional discounts that materially harmed bookings growth. The company's stock declined over 14% on February 25, 2026, following disclosure of sharply decelerated bookings growth of only 5% in Q4 2025. The lead plaintiff deadline is October 20, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| Kaplan Fox Notifies Beta Bionics, Inc. (NASDAQ: BBNX) Investors of an Upcoming Lead Plaintiff Deadline on November 3, 2026 | A class action lawsuit has been filed against Beta Bionics (NASDAQ: BBNX) for investors who purchased stock between July 30, 2025 and February 24, 2026. The complaint alleges the company received thousands of complaints about serious device malfunctions in its iLet insulin pump caused by an overly aggressive dosing algorithm. The FDA issued a warning letter on February 24, 2026 detailing violations and contradicting the company's prior statements about complaint severity, leading to a 37% stock decline. The lead plaintiff deadline is November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| Kaplan Fox Alerts GoDaddy Inc. (NYSE: GDDY) Investors to an Approaching Lead Plaintiff Deadline on October 20, 2026 | A class action lawsuit has been filed against GoDaddy Inc. for allegedly making false and misleading statements about customer growth strategy while implementing promotional discounts that materially harmed bookings growth. The company's stock declined over 14% on February 25, 2026, following disclosure of sharply decelerated bookings growth of only 5% in Q4 2025. The lead plaintiff deadline is October 20, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| Kaplan Fox Notifies Beta Bionics, Inc. (NASDAQ: BBNX) Investors of an Upcoming Lead Plaintiff Deadline on November 3, 2026 | A class action lawsuit has been filed against Beta Bionics (NASDAQ: BBNX) for investors who purchased stock between July 30, 2025 and February 24, 2026. The complaint alleges the company received thousands of complaints about serious device malfunctions in its iLet insulin pump caused by an overly aggressive dosing algorithm. The FDA issued a warning letter on February 24, 2026 detailing violations and contradicting the company's prior statements about complaint severity, leading to a 37% stock decline. The lead plaintiff deadline is November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| רוזן, משרד מוביל בפריסה ארצית המייצג משקיעים, מעודד את משקיעי חברת Beta Bionics, Inc לשכור ייעוץ משפטי לקראת מועד אחרון חשוב במסגרת תביעה ייצוגית בניירות ערך – BBNX | The Rosen Law Firm is reminding investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 of the November 3, 2026 deadline to file a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false and misleading statements about its iLet Bionic Pancreas insulin pump system, which the FDA found to have serious malfunctions causing dangerous insulin levels and hypoglycemic events. The company allegedly failed to implement corrective measures despite FDA concerns. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bearish | -1 | 1 |
| Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX | Beta Bionics faces a securities class action lawsuit alleging the company failed to disclose that its iLet insulin pump had a malfunctioning automated dosing algorithm causing dangerously high insulin delivery and hypoglycemic events. The company allegedly received thousands of complaints it failed to report to the FDA, and an FDA Form 483 identified over 18,000 unreported complaints. Investors with losses exceeding $100,000 have until November 3, 2026 to file lead plaintiff applications. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bearish | -1 | 1 |
| ROSEN, TOP-RANKED TRIAL ATTORNEYS, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS | Rosen Law Firm has filed securities class action lawsuits against Doximity, Inc., Qfin Holdings, Inc., and Beta Bionics, Inc., alleging investor damages. The primary case detailed involves Doximity, which allegedly overstated its Newsfeed's revenue impact and lost market share to competitors. Investors have until November 16, 2026 to serve as lead plaintiff. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bearish | -1 | 1 |
| ROSEN, LEADING INVESTOR COUNSEL, Encourages Qfin Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QFIN | Rosen Law Firm has filed class action lawsuits against Qfin Holdings, Inc. for allegedly making false and misleading statements about business resilience and downplaying regulatory impacts during the Class Period (March 18, 2026 - August 25, 2026). Investors who purchased securities during this period may be eligible for compensation. The deadline to serve as lead plaintiff is November 30, 2026. | View source ↗ | GlobeNewswire Inc. | Sep 30, 2026 | bearish | -1 | 1 |
| ROSEN, A NATIONAL AND LEADING INVESTOR RIGHTS FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX | Rosen Law Firm is soliciting investors in Beta Bionics, Inc. (NASDAQ: BBNX) who purchased stock between July 30, 2025 and February 24, 2026 to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, concealing that the FDA had raised serious safety concerns including device malfunctions causing dangerously high insulin dosing and thousands of complaints. The lead plaintiff deadline is November 3, 2026. | View source ↗ | GlobeNewswire Inc. | Sep 30, 2026 | bearish | -1 | 1 |
| A 4:30 p.m. ET call will review Beta Bionics' third-quarter performance on Oct. 27. - Stock Titan | A 4:30 p.m. ET call will review Beta Bionics' third-quarter performance on Oct. 27. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Robbins LLP Urges BBNX Stockholders to Contact the Firm for Information About the Class Action Against Beta Bionics, Inc. - Morningstar | Robbins LLP Urges BBNX Stockholders to Contact the Firm for Information About the Class Action Against Beta Bionics, Inc. Morningstar | View source ↗ | Morningstar | Sep 29, 2026 | neutral | 0 | 0.6 |
| Beta Bionics (NasdaqGM:BBNX) Stock Forecast & Analyst Predictions - Simply Wall Street | Beta Bionics (NasdaqGM:BBNX) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 29, 2026 | neutral | 0 | 0.6 |
| BBNX Stock Drop Alert: Beta Bionics Stock Plummets 37% - GlobeNewswire | BBNX Stock Drop Alert: Beta Bionics Stock Plummets 37% GlobeNewswire | View source ↗ | GlobeNewswire | Sep 25, 2026 | neutral | 0 | 0.6 |
| A year-long glucose monitor is expected to join an automated insulin system in Q4 - Stock Titan | A year-long glucose monitor is expected to join an automated insulin system in Q4 Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| $BBNX stock is up 7% today. Here's what we see in our data. - Quiver Quantitative | $BBNX stock is up 7% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 15, 2026 | neutral | 0 | 0.6 |
| Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism - Yahoo Finance | Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism Yahoo Finance | View source ↗ | Yahoo Finance | Jul 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.